Literature DB >> 16611919

Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.

Masako Shimamura1, Michael Mach, William J Britt.   

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous human pathogen that infects 40 to 90% of adult human populations. HCMV infections are often asymptomatic in healthy individuals but can cause severe organ and life-threatening disease in immunocompromised patients. The antiviral antibody response to HCMV infection is complex and is known to include virus-neutralizing antibody production against surface glycoproteins encoded by HCMV. We have investigated the human antibody response to a complex of HCMV surface glycoproteins composed of glycoprotein M (gM)/gN, the gene products of the UL100 and UL73 open reading frames. Mouse monoclonal antibodies generated against gM/gN have previously been shown to neutralize HCMV infection of human fibroblasts in vitro. To determine whether human antibodies reactive with the gM/gN complex possess virus-neutralizing properties, we isolated human antibodies reactive with gM/gN from pooled human HCMV hyperimmune globulin by affinity purification using recombinant gM/gN. The affinity-purified human anti-gM/gN antibodies reacted specifically by immunofluorescence with HCMV-infected human fibroblasts and with cells transiently expressing gM/gN, but not with cells transfected with plasmids encoding other immunogenic HCMV proteins. The anti-gM/gN antibodies also reacted specifically only with gM/gN in immunoblot assays using lysates of transfected cells expressing specific HCMV proteins. Last, human anti-gM/gN antibodies efficiently neutralized infectious HCMV in vitro with a capacity comparable to that of human anti-gB antibodies. These data indicated that gM/gN can elicit a virus-neutralizing antibody response in humans infected with HCMV and therefore should be considered a potential candidate for inclusion in prophylactic CMV vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611919      PMCID: PMC1471997          DOI: 10.1128/JVI.80.9.4591-4600.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Immune response to human cytomegalovirus infection.

Authors:  L Rasmussen
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus.

Authors:  M Andreoni; M Faircloth; L Vugler; W J Britt
Journal:  J Virol Methods       Date:  1989-02       Impact factor: 2.014

3.  Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses.

Authors:  R Lehner; H Meyer; M Mach
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Comparative sequence analysis of human cytomegalovirus strains.

Authors:  R Lehner; T Stamminger; M Mach
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

5.  Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects.

Authors:  Michael Mach; Barbara Kropff; Magdalena Kryzaniak; William Britt
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Identification of the major capsid protein gene of human cytomegalovirus.

Authors:  M Chee; S A Rudolph; B Plachter; B Barrell; G Jahn
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans.

Authors:  L Rasmussen; C Matkin; R Spaete; C Pachl; T C Merigan
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

9.  Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II.

Authors:  B Kari; R Gehrz
Journal:  J Gen Virol       Date:  1993-02       Impact factor: 3.891

10.  Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.

Authors:  G S Marshall; G P Rabalais; G G Stout; S L Waldeyer
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

View more
  50 in total

1.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

Review 2.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

3.  Neutralizing activity of saliva against cytomegalovirus.

Authors:  Frances M Saccoccio; Mary K Gallagher; Stuart P Adler; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 4.  Human cytomegalovirus entry into cells.

Authors:  Adam L Vanarsdall; David C Johnson
Journal:  Curr Opin Virol       Date:  2012-01-30       Impact factor: 7.090

5.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 6.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

7.  Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge.

Authors:  Huadong Wang; Yanfeng Yao; Chaoyang Huang; Quanjiao Chen; Jianjun Chen; Ze Chen
Journal:  Virol Sin       Date:  2013-05-24       Impact factor: 4.327

8.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

Authors:  Devon J Shedlock; Kendra T Talbott; Stephan J Wu; Christine M Wilson; Karuppiah Muthumani; Jean D Boyer; Niranjan Y Sardesai; Sita Awasthi; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.